This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
News|Articles|August 9, 2017
AAPS Elects New President for 2017
Author(s)Pharmaceutical Technology Editors
The American Association of Pharmaceutical Scientists (AAPS) announced the election of Dale Eric Wurster, PhD, FAAPS as president-elect of its board of directors.
Advertisement
On August 8, 2017, the American Association of Pharmaceutical Scientists (AAPS) announced the election of Dale Eric Wurster, PhD, FAAPS as president-elect of the association’s board of directors. Starting in November 2017 at the AAPS Annual Meeting and Exposition in San Diego, CA, he will begin a three-year term as president-elect, president and immediate past president. The meeting anticipates an attendance of over 6,500 international pharmaceutical scientists.
“I am heavily invested in the long-term success of AAPS, and I would like very much to be part of the strategizing being undertaken by the leadership team as it attempts to create an even more active and vibrant scientific organization; an organization which will be relevant to academically-diverse individuals well into the 21st century,” said Dr. Wurster in his election bulletin.
In addition to the new president-elect, Reina Bendayan, PharmD, FAAPS from University of Toronto, and Allen C. Templeton, PhD, FAAPS from Merck & Co. were elected as AAPS Members-at-Large.
Source:
Advertisement
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Advertisement
Advertisement